Tandem Diabetes Care

Persistent Pricing Pressure And Commoditization Will Undermine Diabetes Care Outlook

AnalystLowTarget

Not Invested

Consensus Narrative from 21 Analysts

Published

07 Aug 25

Updated

10 Aug 25

AnalystLowTarget's Fair Value

US$10.00

22.4% overvalued

10 Aug

US$12.24

-73.1%

12.4%

-73.1%

12.4%

Author's Valuation

US$10.0

22.4% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$10.0

22.4% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.73%

Medical Equipment revenue growth rate

0.45%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.71%

Calculation

US$145.89m

Earnings '28

6.53x

PE Ratio '28

US$953.39m

Market Cap '28

US$953.39m

Market Cap '28

74.30m

No. shares '28

US$12.83

Share Price '28

US$12.83 Share Price '28

Discounted to 2025 @ 8.81% p.a.

US$9.96

Fair Value '25